

Pamela S Becker

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/591480/pamela-s-becker-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

4,330
citations

35
h-index

61
g-index

233
ext. papers

5,197
ext. citations

4
avg, IF

5.19
L-index

#	Paper	IF	Citations
218	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function.. <i>Cell Stem Cell</i> , 2022 ,	18	2
217	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.. <i>Leukemia Research</i> , 2022 , 115, 106822	2.7	
216	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. <i>Blood</i> , 2021 , 138, 502-502	2.2	
215	Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2021 , 138, 268-268	2.2	
214	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1226-1233	1.9	7
213	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , 2021 , 106, 2114-2120	6.6	3
212	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
211	Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 202-209	4.4	2
210	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>American Journal of Hematology</i> , 2021 , 96, 208-217	7.1	31
209	Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. <i>Blood Advances</i> , 2021 , 5, 687-699	7.8	4
208	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2021 ,	2.2	3
207	Unsupervised discovery of dynamic cell phenotypic states from transmitted light movies.. <i>PLoS Computational Biology</i> , 2021 , 17, e1009626	5	0
206	Envelope-Specific Adaptive Immunity following Transplantation of Hematopoietic Stem Cells Modified with VSV-G Lentivirus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 19, 438-446	6.4	2
205	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020 , 4, 2032-2043	7.8	19
204	Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney. <i>Leukemia</i> , 2020 , 34, 2776-2779	10.7	3
203	Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1728-1731	1.9	0
202	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2	0

201	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 6132-6140	12.9	19
200	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 12-22	7.3	44
199	KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 602-609	2	2
198	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 344-353	12.9	39
197	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020 , 34, 1169-1171	10.7	1
196	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4163-4174	2.2	10
195	Case of Chemotherapy-Refractory, -Mutated Chronic Myelomonocytic Leukemia Responsive to Single-Agent Trametinib Based on Results From a High-Throughput Drug Screen.. <i>JCO Precision Oncology</i> , 2020 , 4, 1367-1373	3.6	1
194	Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. <i>Cancer Medicine</i> , 2020 , 9, 6515-6523	4.8	3
193	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020 , 34, 635-639	10.7	6
192	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020 , 4, 611-616	7.8	10
191	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e633-e635	2	2
190	Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. <i>Blood</i> , 2019 , 134, 186-198	2.2	27
189	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1364-1364	2.2	3
188	High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan. <i>Blood</i> , 2019 , 134, 2690-2690	2.2	5
187	High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1885-1885	2.2	1
186	Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2019 , 134, 230-230	2.2	2
185	Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. <i>Blood</i> , 2019 , 134, 264-264	2.2	12
184	Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 204-204	2.2	42

183	High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1902-1902	2.2	1
182	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019 , 134, 260-260	2.2	2
181	Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1317-1317	2.2	
180	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2650-2650	2.2	1
179	A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia. <i>Blood</i> , 2019 , 134, 1269-1269	2.2	0
178	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019 , 134, 2692-2692	2.2	
177	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. <i>Blood Advances</i> , 2019 , 3, 1939-1949	7.8	39
176	Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Haematologica</i> , 2019 , 104, e143-e146	6.6	9
175	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019 , 133, 7-17	2.2	811
174	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019 , 104, 380-391	6.6	19
173	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1023-1029	1.9	4
172	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1386-1391	4.7	9
171	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Haematologica</i> , 2018 , 103, e106-e109	6.6	18
170	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018 , 93, 546-552	7.1	7
169	A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. <i>Nature Communications</i> , 2018 , 9, 42	17.4	106
168	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 2352-2362	10.7	21
167	Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. <i>Haematologica</i> , 2018 , 103, 1806-1814	6.6	8
166	High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 180-180	2.2	1

165	Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial. <i>Blood</i> , 2018 , 132, 1419-1419	2.2	2
164	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 207-207	2.2	1
163	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. <i>Blood</i> , 2018 , 132, 331-331	2.2	16
162	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , 2018 , 132, 2710-2710	2.2	1
161	Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation. <i>Blood</i> , 2018 , 132, 297-297	2.2	10
160	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1011-1011	2.2	62
159	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. <i>Blood</i> , 2018 , 132, 1513-1513	2.2	2
158	From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi Anemia. <i>Blood</i> , 2018 , 132, 2208-2208	2.2	1
157	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3263-3263	2.2	
156	Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis. <i>Blood</i> , 2018 , 132, 198-198	2.2	
155	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 1388-1388	2.2	
154	Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia. <i>Blood</i> , 2018 , 132, 3992-3992	2.2	1
153	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018 , 132, 3986-3986	2.2	
152	Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study. <i>Blood</i> , 2018 , 132, 2954-2954	2.2	
151	Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2017 , 92, E75-E77	7.1	13
150	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , 2017 , 178, 906-913	4.5	28
149	Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. <i>Leukemia</i> , 2017 , 31, 2560-2567	10.7	22
148	Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. <i>Acta Haematologica</i> , 2017 , 137, 123-131	2.7	3

147	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2717-2719	1.9	7
146	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
145	Controversies Regarding Use of Myeloid Growth Factors in Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1551-1557	7.3	2
144	A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 59-65	4.4	12
143	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1520-1541	7.3	76
142	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. <i>Blood</i> , 2017 , 130, 894-894	2.2	8
141	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017 , 130, 910-910	2.2	5
140	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017 , 1, 2247-2256	7.8	11
139	GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2520-2520	2.2	3
138	GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2560-2560	2.2	6
137	Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7027-7027	2.2	4
136	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. <i>Current Gene Therapy</i> , 2017 , 16, 338-348	4.3	24
135	A randomized study of melphalan 200 mg/m ² vs 280 mg/m ² as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. <i>Bone Marrow Transplantation</i> , 2016 , 51, 67-71	4.4	19
134	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2016 , 172, 134-6	4.5	5
133	The Role of Biosimilars. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 626-9	7.3	5
132	Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. <i>British Journal of Haematology</i> , 2016 , 172, 238-45	4.5	22
131	Radioimmunotherapy consolidation using ¹³¹ I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. <i>Leukemia and Lymphoma</i> , 2016 , 57, 572-6	1.9	8
130	A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2016 , 128, 1068-1068	2.2	1

129	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
128	Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience. <i>Blood</i> , 2016 , 128, 3377-3377	2.2	2
127	Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps. <i>Blood</i> , 2016 , 128, 3510-3510		6
126	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. <i>Blood</i> , 2016 , 128, 4049-4049	2.2	4
125	Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin. <i>Blood</i> , 2016 , 128, 5063-5063	2.2	1
124	Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander? 2016 , 13,		2
123	A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study. <i>Blood</i> , 2016 , 128, 2787-2787	2.2	
122	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. <i>Blood</i> , 2016 , 128, 2792-2792	2.2	
121	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 4043-4043	2.2	
120	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. <i>Blood</i> , 2016 , 128, 1064-1064	2.2	
119	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 8-17	7.3	17
118	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society for Amyloidosis</i> , 2016 , 23, 251-259	2.7	4
117	A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e422	7	5
116	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1205-7	1.9	1
115	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology,the</i> , 2016 , 3, e330-9	14.6	21
114	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e97-8	6.6	8
113	Sparse expression bases in cancer reveal tumor drivers. <i>Nucleic Acids Research</i> , 2015 , 43, 1332-44	20.1	20
112	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 263-70	1.9	8

111	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1258-64	2.2	163
110	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e254-6	6.6	3
109	JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?. <i>JAMA Oncology</i> , 2015 , 1, 651-2	13.4	5
108	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. <i>JAMA Oncology</i> , 2015 , 1, 1120-7	13.4	33
107	Management of Acute Myeloid Leukemia in the Intensive Care Setting. <i>Journal of Intensive Care Medicine</i> , 2015 , 30, 375-84	3.3	5
106	A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. <i>British Journal of Haematology</i> , 2015 , 170, 349-55	4.5	7
105	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015 , 90, 483-6	7.1	19
104	Panobinostat: a review of trial results and future prospects in multiple myeloma. <i>Expert Review of Hematology</i> , 2015 , 8, 9-18	2.8	26
103	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2015 , 90, 295-300	7.1	15
102	A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 3809-3809	2.2	7
101	Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD. <i>Blood</i> , 2015 , 126, 2498-2498	2.2	
100	Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage. <i>Blood</i> , 2015 , 126, 3629-3629	2.2	
99	Toward Individualized Therapy: Correlation of Mutation Analysis with in Vitro high Throughput Drug Sensitivity Testing in New Diagnosis and Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3851-3851	2.2	
98	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 1339-1339	2.2	
97	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , 2014 , 166, 375-81	4.5	1
96	Optimizing stem cell mobilization: lessons learned. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1443-9	7.3	
95	Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma. <i>Cancer Treatment Communications</i> , 2014 , 2, 34-47		22
94	Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1183-9	4.7	76

93	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3483-3483	2.2	13
92	Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2014 , 124, 3732-3732	2.2	1
91	Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 386-386	2.2	39
90	Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality. <i>Blood</i> , 2014 , 124, 994-994	2.2	1
89	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study. <i>Blood</i> , 2014 , 124, 3730-3730	2.2	
88	Feasibility Trial of Individualized Therapy for Relapsed or Refractory Acute Myeloid Leukemia Based on a High Throughput in Vitro Drug Sensitivity Assay. <i>Blood</i> , 2014 , 124, 3748-3748	2.2	1
87	Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones. <i>Blood</i> , 2014 , 124, 2372-2372	2.2	
86	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013 , 2, 26-8	0.6	2
85	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3883-8	2.2	35
84	Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM). <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S154	4.7	4
83	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013 , 163, 130-2	4.5	
82	Myeloid growth factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1266-903	2.3	49
81	Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. <i>Haematologica</i> , 2013 , 98, 114-8	6.6	18
80	Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 3882-3882	2.2	6
79	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. <i>Blood</i> , 2013 , 122, 483-483	2.2	2
78	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013 , 122, 5002-5002	2.2	1
77	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013 , 122, 61-61	2.2	19
76	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013 , 122, 3926-3926	2.2	

75	131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission. <i>Blood</i> , 2013 , 122, 1644-1644	2.2	
74	Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2578-2578	2.2	
73	Cost and Utilization Of Stored Autologous PBSC To Support Tandem ASCT In MM Patients In The Era Of Novel Agent Therapy. <i>Blood</i> , 2013 , 122, 4507-4507	2.2	
72	Immune defects in a mouse model of Fanconi anaemia. <i>British Journal of Haematology</i> , 2012 , 159, 246-504.5	3	
71	A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 159, 58-66	4.5	92
70	Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. <i>Journal of Molecular Medicine</i> , 2012 , 90, 1283-94	5.5	9
69	Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. <i>Scientific World Journal, The</i> , 2012 , 2012, 856467	2.2	42
68	Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β -thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. <i>Molecular Therapy</i> , 2012 , 20, 230-8	11.7	54
67	Cancer- and chemotherapy-induced anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 628-53	7.3	117
66	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 1418-1418	2.2	2
65	Randomized Comparison of Melphalan 200 Mg/m ² v. 280 Mg/m ² As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 2009-2009	2.2	1
64	Lenalidomide Is Effective Therapy for Relapse After Allogeneic Stem Cell Transplant for Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 3064-3064	2.2	1
63	A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2Rgc α Mice Engrafted with Human AML. <i>Blood</i> , 2012 , 120, 4092-4092	2.2	7
62	NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012 , 120, 1479-1479	2.2	
61	A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma. <i>Blood</i> , 2012 , 120, 5038-5038	2.2	
60	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.. <i>Blood</i> , 2012 , 120, 2598-2598	2.2	
59	Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF).. <i>Blood</i> , 2012 , 120, 2499-2499	2.2	
58	Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center. <i>Blood</i> , 2012 , 120, 2016-2016	2.2	

57	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2012 , 120, 3594-3594	2.2	
56	A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.. <i>Blood</i> , 2012 , 120, 2590-2590	2.2	
55	The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.. <i>Blood</i> , 2012 , 120, 2596-2596	2.2	
54	Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011 , 155, 182-9	4.5	68
53	Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. <i>Leukemia Research</i> , 2011 , 35, e164-6	2.7	4
52	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. <i>Cancer</i> , 2011 , 117, 992-1000	6.4	58
51	Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. <i>Molecular Therapy</i> , 2011 , 19, 1193-8	11.7	33
50	Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 783-6	2.2	13
49	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011 , 118, 2772-2772	2.2	5
48	Infusion of Buff-the-shelf Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML,. <i>Blood</i> , 2011 , 118, 3640-3640	2.2	1
47	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. <i>Blood</i> , 2011 , 118, 82-82	2.2	11
46	Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2R β Knockout and Confer Susceptibility to Cytarabine. <i>Blood</i> , 2011 , 118, 579-579	2.2	
45	Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. <i>British Journal of Haematology</i> , 2010 , 148, 944-7	4.5	37
44	Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. <i>British Journal of Haematology</i> , 2010 , 149, 706-10	4.5	38
43	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 437-44	2.2	154
42	Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2010 , 116, 1885-1885	2.2	2
41	CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2010 , 116, 1056-1056	2.2	
40	Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.. <i>Blood</i> , 2010 , 116, 1065-1065	2.2	

39	Multiple myeloma and Gaucher genes. <i>Genetics in Medicine</i> , 2009 , 11, 134	8.1	10
38	Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. <i>Blood</i> , 2009 , 113, 866-74	2.2	55
37	G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009 , 114, 2068-2068	2.2	3
36	An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009 , 114, 2765-2765	2.2	1
35	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. <i>Blood</i> , 2009 , 114, 4332-4332	2.2	
34	Limitations of G-CSF Mobilization in Splenectomized Patients with Beta-Thalassemia Major: Implications for Thalassemia Gene Therapy.. <i>Blood</i> , 2009 , 114, 2150-2150	2.2	
33	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009 , 114, 2658-2658 ⁰	2.2	
32	Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2964-2964	2.2	1
31	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008 , 112, 858-858	2.2	4
30	A Phase II Study of Bortezomib (Velcade [®]), Cyclophosphamide (Cytoxan [®]), Thalidomide (Thalomid [®]) and Dexamethasone as First-Line Therapy for Multiple Myeloma. <i>Blood</i> , 2008 , 112, 94-94	2.2	7
29	Cancer- and chemotherapy-induced anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 536-64	7.3	26
28	Correction of Fanconi Anemia Group A in Primary Human and Murine Hematopoietic Progenitors with a Clinical Lentiviral Vector. <i>Blood</i> , 2008 , 112, 2357-2357	2.2	
27	Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.. <i>Blood</i> , 2007 , 110, 1452-1452	2.2	7
26	Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.. <i>Blood</i> , 2007 , 110, 250-250	2.2	22
25	Inhibition of $\alpha 5 \beta 1$ Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells.. <i>Blood</i> , 2007 , 110, 4805-4805	2.2	
24	Adhesion receptor expression by CD34+ cells from peripheral blood or bone marrow grafts: correlation with time to engraftment. <i>Experimental Hematology</i> , 2006 , 34, 680-7	3.1	13
23	A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3575-3575	2.2	11
22	The current status of gene therapy in autologous transplantation. <i>Acta Haematologica</i> , 2005 , 114, 188-197.	7.7	12

21	Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. <i>Cancer Research</i> , 2005 , 65, 358-63	10.1	63
20	Stem cells and prenatal origin of breast cancer. <i>Cancer Causes and Control</i> , 2004 , 15, 517-30	2.8	39
19	A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells. <i>Stem Cells</i> , 2004 , 22, 1030-8	5.8	73
18	Transfer of the Multidrug Resistance Gene, MDR-1, to Hematopoietic Progenitors from a Patient with Transformed Large Cell Lymphoma, and Demonstration of In Vivo Chemotherapy Protection with Dose Escalating Chemotherapy.. <i>Blood</i> , 2004 , 104, 5278-5278	2.2	4
17	Growth factor priming in therapy of acute myelogenous leukemia. <i>Psychophysiology</i> , 2004 , 3, 413-8		9
16	Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1563-72	16.6	71
15	Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. <i>Blood</i> , 2002 , 100, 442-50	2.2	42
14	Homing of purified murine lymphohematopoietic stem cells: a cytokine-induced defect. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002 , 11, 913-22		46
13	The new stem cell biology. <i>Transactions of the American Clinical and Climatological Association</i> , 2002 , 113, 182-206; discussion 206-7	0.9	12
12	Variables to predict engraftment of umbilical cord blood into immunodeficient mice: usefulness of the non-obese diabetic--severe combined immunodeficient assay. <i>British Journal of Haematology</i> , 2001 , 114, 211-8	4.5	24
11	The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. <i>Experimental Hematology</i> , 2001 , 29, 1326-35	3.1	64
10	Physical and physiological plasticity of hematopoietic stem cells. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 934-7	2.1	18
9	Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. <i>British Journal of Haematology</i> , 2000 , 108, 629-40	4.5	15
8	Successful autologous bone marrow transplant without the use of blood product support. <i>Bone Marrow Transplantation</i> , 2000 , 26, 227-9	4.4	21
7	Lymphohematopoietic stem cell engraftment. <i>Annals of the New York Academy of Sciences</i> , 1999 , 872, 40-5; discussion 45-7	6.5	15
6	Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status. <i>Experimental Hematology</i> , 1999 , 27, 533-41	3.1	123
5	Coverage of bone marrow transplant patients: a survey of American and Canadian institutions. <i>Biology of Blood and Marrow Transplantation</i> , 1998 , 4, 49-55	4.7	1
4	Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. <i>Journal of Histochemistry and Cytochemistry</i> , 1998 , 46, 371-7	3.4	136

- 3 Giant platelets with abnormal surface glycoproteins: a new familial disorder associated with mitral valve insufficiency. *Journal of Pediatric Hematology/Oncology*, **1998**, 20, 69-73 1.2 7
- 2 Radiolabel-transfer cross-linking demonstrates that protein 4.1 binds to the N-terminal region of beta spectrin and to actin in binary interactions. *FEBS Journal*, **1990**, 193, 827-36 38
- 1 High yield purification of protein 4.1 from human erythrocyte membranes. *Analytical Biochemistry*, **1983**, 132, 195-201 3.1 22